[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542947":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":36,"locations":43,"responsibleParty":61,"collaborators":29,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":29,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":29,"enrollmentInfo":74,"targetDuration":29,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":29,"overallStatus":46,"whyStopped":29,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Kaohsiung Medical University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"bismuth-amoxicillin-vonoprazan triple therapy","ACTIVE_COMPARATOR","vonoprazan 20mg twice a day + amoxicillin 750mg four times a day + tripotassium dicitrate bismuthate 300mg four times a day",[13],"Drug: vonoprazan, amoxicillin, tripotassium dicitrate bismuthate",{"label":15,"type":10,"description":16,"interventionNames":17},"vonoprazan-amoxicillin dual therapy","vonoprazan 20mg twice a day + amoxicillin 750mg，Four times a day",[18],"Drug: vonoprazan, amoxicillin",{"label":20,"type":10,"description":21,"interventionNames":22},"proton pump inhibitor-based standard triple therapy","rabeprazole 20mg twice a day + amoxicillin 1gm twice a day + clarithromycin 500mg twice a day",[23],"Drug: rabeprazole, amoxicillin, clarithromycin",[25,30,33],{"type":26,"name":27,"description":9,"armGroupLabels":28,"otherNames":29},"DRUG","vonoprazan, amoxicillin, tripotassium dicitrate bismuthate",[9],null,{"type":26,"name":31,"description":15,"armGroupLabels":32,"otherNames":29},"vonoprazan, amoxicillin",[15],{"type":26,"name":34,"description":20,"armGroupLabels":35,"otherNames":29},"rabeprazole, amoxicillin, clarithromycin",[20],[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Deng-Chyang Wu, MD, PHD","CONTACT","88673121101","7451","dechwu@yahoo.com",[44],{"facility":45,"status":46,"city":47,"state":29,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Kaohsiung Medical University Hospital","RECRUITING","Kaohsiung City","807","Taiwan","TW",{"type":52,"coordinates":53},"Point",[54,55],120.31333,22.61626,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":60,"phoneExt":41,"email":42},"Deng-Chyang Wu, MD,PHD","886-7-3121101",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","DENG-CHYANG WU","clinical professor","100542947","efficacies-of-bismuth-amoxicillin-vonoprazan-triple-therapy-vonoprazan-amoxicillin-dual-therapy-and-proton-pump-inhibitor-based-standard-triple-therapy-for-hp-eradication-100542947",false,"NCT06349486","Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy in the First-line Anti-H. Pylori Treatment","Inclusion Criteria:\n\n(1) At least 18 years old. (2) Subjects infected with Helicobacter pylori.\n\nExclusion Criteria:\n\n1. Those who have ever received Helicobacter pylori sterilization treatment.\n2. Those who are allergic to the drugs used in this research.\n3. Those who have had stomach surgery.\n4. Those with severe liver cirrhosis or uremia or malignant tumors.\n5. Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":75,"type":76},390,"ESTIMATED","INTERVENTIONAL",[79],"NA","1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection.\n2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.",[82],"Helicobacter Pylori Eradication","2026-01-13",{"date":85,"type":86},"2026-01-15","ACTUAL",{"date":88,"type":86},"2023-11-28",{"date":90,"type":76},"2026-12-31",{"name":5,"class":6},1]